[Taylor&Francis] Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis |
|
This post will be closed automatically in 2026-07-29 00:08
Best Answer
5 day(s) ago
|
| |
post
reply
points
10
30
Generative AI-Driven resilience in supply chain management: UNISONE framework for disruption modelling and capacity optimisation
30
Fremanezumab for migraine in clinical practice: a systematic review and meta-analysis
30
Post-pandemic crisis communication strategy for the domestic market of Thai urban beach city
30
Adaptive changes of organelles induced by gold nanoparticles
50
[Full book]Carbon Fibers and Their Composites
